Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)
- Kathleen I Pritchard, MD, FRCPC
Kathleen I Pritchard, MD, FRCPC
- Professor; Departmental Division Director, Medical Oncology
- Department of Medicine, University of Toronto
- Medical Oncologist and Senior Scientist
- Sunnybrook Odette Cancer Centre
- Toronto, Canada
- Section Editor
- Daniel F Hayes, MD
Daniel F Hayes, MD
- Section Editor — Breast Cancer
- Professor of Medicine
- University of Michigan School of Medicine
- Deputy Editor
- Don S Dizon, MD, FACP
Don S Dizon, MD, FACP
- Deputy Editor — Oncology and Palliative Care
- Medical Gynecologic Oncology
- Massachusetts General Hospital
- Gillette Center for Women's Cancers
- Associate Professor, Medicine & Obstetrics and Gynecology
- Warren Alpert Medical School of Brown University
Breast cancer is the most common female cancer in the United States. Finding and treating breast cancer in the early stages allows many women to be cured.
Following surgery, systemic (body-wide) anticancer treatment is often recommended to eliminate any microscopic tumor cells that might remain in the body. This type of therapy is called adjuvant therapy, and it is a very important component of breast cancer treatment. Adjuvant systemic therapy significantly decreases the chance that the cancer will return (or recur), and it also improves a woman's chance of surviving her cancer.
There are three options for systemic adjuvant therapy of early breast cancer: endocrine therapy, chemotherapy, and trastuzumab (Herceptin). The choice between these treatments depends upon whether the breast cancer is hormone-responsive and whether it makes a protein called HER2.
This article will focus on adjuvant therapy for premenopausal women with hormone-responsive breast cancer. Adjuvant treatment for postmenopausal women with hormone-responsive breast cancer is discussed separately. (See "Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)".)
DEFINING HORMONE-RESPONSIVE BREAST CANCER
About 50 to 70 percent of breast cancers require the female hormone estrogen (estradiol) to grow, while other breast cancers are able to grow without estrogen. Estrogen-dependent breast cancer cells produce hormone receptors, which can be estrogen receptors (ER), progesterone receptors (PR), or both. These cancers are known as "hormone-responsive".
If your breast cancer is hormone-responsive, you are more likely to benefit from treatments that lower estrogen levels or block the actions of estrogen. These treatments are referred to as endocrine or hormone therapies.
ENDOCRINE THERAPY OPTIONS
The goal of adjuvant endocrine therapy is to prevent breast cancer cells from receiving stimulation from estrogen.
The options for endocrine therapy in premenopausal women include the following:
●The drug tamoxifen
●A drug or surgery that prevents the ovaries from making estrogen (see 'Ovarian suppression' below)
Tamoxifen — Tamoxifen (Nolvadex) prevents estrogen from stimulating growth of the breast cancer cells.
Tamoxifen has been recommended for five years, and the benefits last for at least 10 years after the drug is stopped. However, newer studies show that taking tamoxifen for more than five years does add further benefit, although the risk of side effects such as uterine cancer increases with longer treatment.
Side effects — Tamoxifen may increase the risk of the following, particularly in women over age 55 years:
●Cancer of the uterus (endometrial cancer and sarcoma)
●Blood clots within deep veins (deep vein thrombosis), usually in the legs, which can travel to the lungs (pulmonary embolism) (see "Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)")
●Whether tamoxifen increases the risk of stroke, particularly in women under the age of 55, is controversial.
For most women, the benefits of tamoxifen in preventing a recurrence of breast cancer far outweigh the risks of uterine cancer, blood clots, or other long-term effects. However, the risks may be higher for women with risk factors for blood clots or stroke (eg, prior history of blood clots in the leg or lung, history of smoking).
Tamoxifen may cause other side effects, particularly hot flashes and vaginal discharge. Premenopausal women receiving adjuvant tamoxifen are discouraged from becoming pregnant. Tamoxifen does not cause infertility. Premenopausal women who are taking tamoxifen and are sexually active should use effective nonhormonal contraception while they are on tamoxifen and for about two months after discontinuing the therapy.
Ovarian suppression — Ovarian suppression refers to any treatment that causes the ovaries to stop making estrogen. The ovaries can be suppressed in one of several ways:
●Surgical removal of the ovaries (called oophorectomy) or radiation treatment of the ovaries, both of which permanently stop the ovaries from making hormones.
●Drugs called gonadotropin releasing hormone (GnRH) agonists stop the ovaries from making estrogen temporarily. The most commonly used drug in this class is goserelin (Zoladex), which is given as a monthly injection. The treatment is usually given for five years.
For some patients with a breast cancer that may place them at a higher than average risk of recurrence (including those who are 35 years or younger or who underwent chemotherapy), ovarian suppression plus the aromatase inhibitor (AI), exemestane, may be recommended by your doctor. Of note, all forms of ovarian suppression cause a rapid onset of menopause symptoms (hot flashes, night sweats, mood swings, vaginal dryness), which can be severe. Treatment for these symptoms is available. (See "Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)".)
Aromatase inhibitors — A class of drugs that is used for endocrine therapy in POSTmenopausal women is the aromatase inhibitors (including anastrozole, letrozole or exemestane). In general, aromatase inhibitors are not given alone to premenopausal women.
However, women who are premenopausal before treatment may become menopausal; an aromatase inhibitor may then be considered. You should discuss the indications, risks, and benefits of this option with your doctor.
ENDOCRINE THERAPY OR CHEMOTHERAPY OR BOTH?
Endocrine therapy is recommended for women with ER-positive breast cancer. However, it is not clear if additional treatment (chemotherapy) is also needed.
●Most doctors agree that endocrine therapy alone is adequate for premenopausal women with low-risk tumors (ie, those that are node-negative, ER/PR-positive, small (less than 1 cm) and lacking unfavorable microscopic features) [1,2].
●It is not clear if endocrine therapy alone is enough for women with higher risk ER-positive breast cancers (ie, those with involved lymph nodes, tumor size larger than 1 cm, or unfavorable microscopic features). Chemotherapy certainly provides benefit for some women with ER-positive early breast cancer.
Two tests are available that can help in deciding if chemotherapy might be helpful.
●A test called the 21-gene recurrence score assay (also called Oncotype DX™) may be useful to select those women with ER-positive, node-negative early breast cancer who stand to benefit the most from chemotherapy.
●A web-based assessment program (Adjuvant! Online, www.adjuvantonline.com) is available that can assist in estimating the relative risks and benefits of chemotherapy (as well as endocrine therapy).
Progress in treating breast cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials or read about clinical trials at:
FOLLOW-UP AFTER TREATMENT
A summary of the American Society of Clinical Oncology's recommendations for surveillance after breast cancer treatment is provided in the following table (table 1).
There are many options for the adjuvant therapy of breast cancer. Expert guidelines can help to guide decisions. However, because individual factors strongly influence the choice of therapy, you should discuss the options for adjuvant therapy with your doctor to determine which therapy is best for you.
WHERE TO GET MORE INFORMATION
Your healthcare provider is the best source of information for questions and concerns related to your medical problem.
This article will be updated as needed on our web site (www.uptodate.com/patients). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.
Patient level information — UpToDate offers two types of patient education materials.
The Basics — The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.
Patient information: Breast cancer (The Basics)
Patient information: Breast reconstruction after mastectomy (The Basics)
Patient information: Choosing treatment for early-stage breast cancer (The Basics)
Patient information: Ductal carcinoma in situ (DCIS) (The Basics)
Beyond the Basics — Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.
Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)
Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)
Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)
Professional level information — Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.
Adjuvant medical therapy for HER2-positive breast cancer
Overview of the treatment of newly diagnosed, non-metastatic breast cancer
Breast reconstruction: Preoperative assessment
Diagnostic evaluation of women with suspected breast cancer
Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy
Breast conserving therapy
Acute side effects of adjuvant chemotherapy for early stage breast cancer
Tumor node metastasis (TNM) staging classification for breast cancer
The following organizations also provide reliable health information.
●National Cancer Institute
●The American Society of Clinical Oncology
●National Comprehensive Cancer Network
●American Cancer Society
●National Library of Medicine
●Susan G. Komen Breast Cancer Foundation
- National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on April 01, 2014).
- Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133.
- Enrollment information for the TEXT and SOFT trials summarized at www.youngsurvival.org/research/current-studies/clinical-trial-listing/ (Accessed on September 22, 2011).
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.
- Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.
- Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.
- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:805.
All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.